Clinical Trial Update: Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating Ociperlimab plus Tislelizumab with chemoradiotherapy in untreated limited-stage small cell lung cancer; results have been posted after …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Limited-stage Small Cell Lung Cancer

Drugs mentioned

• Ociperlimab (ociperlimab)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: BeiGene | Conditions: Limited Stage Small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2024-09-19